Patent ID: 7541018

Claim:
A method for treating a cancerous disease, comprising: exposing one or more somatostatin receptors within a cancerous cell to a pharmaceutical composition comprising a somatostatin analogue, wherein the somatostatin analogue binds to the one or more somatostatin receptors and has the general formula: wherein: Z is optionally present or absent and when present is selected from the group consisting of DOTA-based chelators, DTPA-based chelators, NOTA-based chelators carbonyl compounds, hydrazino nicotinamide, N 4 -chelators, desferrioxamine, N X S Y -chelators, tyrosine for halogenation, a fluorescent dye, and biotin; L is optionally present or absent and when present is a linker molecule; X1 is a symmetric or asymmetric diamino acid containing 3 or 4 consecutive carbon atoms; X2 is a positively charged natural or unnatural amino acid, an arginine mimic, citrulline, or a neutral amino acid; X3 is phenylalanine, Ala-[3-(2-thienyl)], α-naphthylalanine, or β-naphthylalanine; X4 is an aromatic amino acid; X5 is threonine or serine; and X6 is phenylalanine, Ala-[3-(2-thienyl)], α-naphthylalanine, or β-naphthylalanine.